Doctor of Medicine, Chief Physician/Associate Professor, Deputy Director of VIP-II Ward **Specialty Expertise** Previously studied at the School of Medicine, Cardiff University, UK, focusing on tumor angiogenesis and metastasis mechanisms. Authored dozens of research papers, and led or participated in multiple basic research and clinical studies. Specializes in medical oncology for digestive system tumors. Possesses extensive clinical experience in treating esophageal cancer, gastric cancer, colorectal cancer, and hepatobiliary-pancreatic malignancies. Utilizes chemotherapy, targeted therapy, and immunotherapy to implement preoperative neoadjuvant therapy, postoperative adjuvant therapy, conversion therapy for oligometastatic patients, and multidisciplinary comprehensive treatment for advanced tumors. **Major Academic Appointments** 1) Secretary-General, Beijing Anti-Cancer Association, Esophageal Cancer Professional Committee. 2) Standing Committee Member, Beijing Cancer Prevention and Treatment Association, Metastatic Liver Cancer Professional Committee. 3) Vice Chairman, Chinese Anti-Cancer Association, Oncology Supportive Therapy Internal Medicine Professional Committee. 4) Member, Chinese Society of Clinical Oncology (CSCO), Vascular Targeted Therapy Expert Committee. 5) Member, Chinese Anti-Cancer Association, Medical Oncology Professional Committee. **Major Academic Achievements** 1) Large cell neuroendocrine carcinoma transformation: A novel acquired drug resistance mechanism in colorectal adenocarcinoma. Cancer Innov. 2023 Mar 20;2(2):159-164. (Corresponding Author) 2) Clinical analysis of immune-related adverse events in gastrointestinal tumors [J]. Journal of Capital Medical University, 2023,44(02):343-350. (Corresponding Author) 3) Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study. J Cancer. 2019; 10(6): 1409–1416. (Co-first Author) 4) Promotion of Cellular Growth and Motility Is Independent of Enzymatic Activity of Fibroblast Activation Protein-α. Cancer Genomics Proteomics. 2016 05-06;13(3):201-208. (Corresponding Author) 5) Study on the signaling pathway of tumor cell migration regulated by membrane surface protease (Seprase). Beijing Natural Science Foundation, (Project Leader)